Direkt zum Inhalt
Merck

PHR1624

Supelco

cis-Diamminplatin(II)-dichlorid

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(e):

cis-Dichlordiamminplatin(II), cis-Platin(II)-diammin-dichlorid, Cisplatin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Lineare Formel:
Pt(NH3)2Cl2
CAS-Nummer:
Molekulargewicht:
300.05
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

certified reference material
pharmaceutical secondary standard

Qualitätsniveau

Agentur

traceable to Ph. Eur. C2210000
traceable to USP 1134357

API-Familie

cisplatin

Analysenzertifikat (CofA)

current certificate can be downloaded

Verpackung

pkg of 200 mg

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

mp (Schmelzpunkt)

270 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-30°C

SMILES String

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChIKey

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Cisplatin is an antineoplastic drug used for the treatment of cancer patients with a variety of different malignancies.

Anwendung

Cisplatin may be used as an analytical reference standard for the determination of the analyte in plasma, cancer cell, and tumor samples by high-performance liquid chromatographic assay.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem./physiol. Wirkung

Wirksames Platin-basiertes Antineoplastikum. Bildet mit dem DNA-Dinukleotid d(pGpG) zytotoxischen Addukte, induziert Intrastrang-Quervernetzung.

Hinweis zur Analyse

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Sonstige Hinweise

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Fußnote

To see an example of a Certificate of Analysis for this material enter LRAB7778 in the slot below. This is an example certificate only and may not be the lot that you receive.

Piktogramme

Skull and crossbonesHealth hazard

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
Jessica M Rusert et al.
Cancer research, 80(23), 5393-5407 (2020-10-14)
Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive
Adrián E Granada et al.
Molecular biology of the cell, 31(8), 845-857 (2020-02-13)
DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.